MedTrace Logo

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

NCT00153088 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 527

Last updated 2013-11-01

No results posted yet for this study

Summary

The aim of this study is to compare the preventive effect of Telmisartan(Micardis) versus placebo control on the transition to overt nephropathy in patients with diabetic nephropathy manifesting microalbuminuria associated with type II diabetes, and to evaluate the efficacy and safety of Telmisart (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) for diabetic nephropathy patients.

Conditions

  • Diabetic Nephropathies

Interventions

DRUG

Telmisartan capsule 40 mg

DRUG

Placebo

DRUG

Telmisartan capsule 80 mg

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator · Nippon Boehringer Ingelheim Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2005-11-30
Completion
2005-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00153088 on ClinicalTrials.gov